Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
Pfizer announces the 'Amaryllis' trial of a PDE-10 inhibitor drug failed to improve symptoms of HD
HDBuzz helps untangle some bold claims about the just-announced results of the PRIDE-HD trial of pridopidine in HD
A new population study reveals that relatively mild forms of the HD mutation are much more common than we thought
HDBuzz summarizes the science from an unusually large and energized @HDSA convention in Baltimore
A confusing story about a huntingtin lowering trial is published in the Telegraph, but cool new stuff is happening!
Stem cells and modeling Huntington's disease in our final Therapeutics Conference report
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.